Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cannabinoids, particularly those derived from the cannabis plant such as THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), have been investigated for their potential role in managing symptoms associated with Multiple Sclerosis (MS). Several randomized controlled trials and systematic reviews have evaluated the efficacy of cannabinoids in treating symptoms like muscle spasticity and pain in MS patients. The best evidence supports their use in alleviating patient-reported spasticity and certain types of pain, though objective improvements in spasticity measured by clinicians are less consistently observed. Products such as nabiximols (a standardized cannabinoid oromucosal spray) are approved in some countries for MS-related spasticity, especially when other treatments have failed. However, the therapeutic benefits are generally modest, and cannabinoids are not considered first-line therapy. Side effects, including dizziness, dry mouth, and cognitive disturbance, are common and can limit tolerability. The National Institute for Health and Care Excellence (NICE) and other authorities recognize the potential benefit for certain symptoms but recommend careful patient selection. Overall, there is scientific validation for the use of cannabinoids in symptom management for MS, but the strength of the evidence is moderate (rated 3/5), and cannabinoids do not alter the progression of the disease itself.

More about Cannabinoids
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Cannabinoids

Products containing Cannabinoids